Advertise on podcast: The Lens: Life Sciences Reinvention in Focus

Mike Blue, CEO of HistoSonics, joins Tom Lehmann to share how the company recovered from an early pivotal-study setback and built histotripsy into a commercial medtech platform that is now redefining cancer treatment. He traces the decisions that changed the trajectory, from rebuilding the technology and proving it in liver tumors to preparing reimbursement, sales and training ahead of FDA clearance. Executive listeners will gain a practical view of how leadership, capital discipline and evidence-building can turn a difficult inflection point into a scalable growth strategy.

The road from therapies to patients continues beyond the lab and the clinic. Anne Marie O'Halloran joins Tom Lehmann to discuss why CMC and manufacturing are critical and what it takes to scale biopharma production using intelligent technologies.

Join Tom Lehmann and brothers Kyle and Brent Pease, co-founders of The Kyle Pease Foundation, as they share how 150+ races together sparked a 15-year movement advancing inclusion in sports and employment for people with disabilities.

What happens after a prescription is written? Pius Hornstein and Fabrice Bocquillon join Tom Lehmann to discuss how Sanofi is closing patient care gaps through personalized AI support and a reimagined patient experience.

Tom Lehmann and Matteo di Tommaso, SVP and Head of Research and Development IT, at Bristol-Myers Squibb, explore approaches to scale AI across drug development, discussing a predict-first mindset to human-led platforms driving real impact on how medicines reach patients.

Join Tom Lehmann and Petra Jantzer, Accenture's Global Life Sciences Lead, as they cover the highlights of 2025 and look forward to 2026. What's coming next for biopharma? Tune in for the trends and insights that will shape the future.

Join Roy Helmy, Associate VP at Merck, as he explores what it takes to reinvent the lab from the ground up. From AI to end-to-end digital transformation of lab operations, Roy shares actionable insights on overcoming resistance and fostering collaboration, and why learning from failure is key to innovation.

In this episode, host Tom Lehmann speaks with Sanjay Patel, Global Head of Innovation Capability Solutions & Services at Takeda, regarding how global collaboration and innovative leadership are reshaping the biotech landscape. Sanjay shares insights into the five-hub network he's building to strengthen Takeda's data, AI, and product-engineering capabilities through Innovation Capability Centers (ICCs). He discusses the impact of AI and emerging technologies, including Takeda's internal GenAI assistant "MyAibou," and how thoughtfully designed workspaces are helping overcome return-to-office fatigue. Tune in for candid lessons on scaling innovation, breaking silos, and keeping curiosity at the core—plus how patient-centered solutions like the "For You, With You: IBD" app are changing lives.

Discover how digital innovation and Gen AI are reshaping pharma with Anvita Karara. Explore how patient-centricity, personalization, and responsible AI are driving better health outcomes and transforming engagement at scale.

An episode with Tracy Ring, Accenture's Chief Data Officer and Global Generative AI Lead for Life Sciences explores how advanced AI, cognitive digital brains, and agentic systems are transforming business efficiency, trust, and customer interactions.

A discussion with David Hole, Global Life Sciences T&O lead about how GenAI is transforming the life sciences workforce, emphasizing the need for new skills, ethical considerations, and the balance between democratization and governance.

Matt Studney, from Merck's Research Laboratories Information Technology discusses AI's growing role in pharma and the need for responsible implementation to enhance health outcomes.

Explore how Genentech's digital cell and gene therapy innovation scales life-saving treatments. From virtual journeys to secure supply chains, learn about the tech and collaborations bringing new therapies safely to patients worldwide.

Just like the life sciences industry, the Driving Digital in Biopharma series has evolved. In each episode, we'll explore the way the industry is being reimagined and reinvented. If you're passionate about the future of medicines and medical technologies, improving patient outcomes and pushing the limits of innovation, The Lens is your essential listen.

In this insightful episode of Driving Digital in Biopharma, host Tom Lehmann explores with Áine Hanly, Chief Technology Officer at Vir Biotechnology, the transformative role of data and technology in drug development and manufacturing. Áine delves into the advancements in data accessibility and automation, such as single-cell manipulation and high throughput processes, which have notably shortened cycle times and boosted efficiency. She also discusses the innovative use of the Vir AI tool Daisy for antibody design and optimization, which speeds up the process and enhances manufacturability. The episode wraps up by highlighting the critical importance of a robust data strategy and the power of cross-functional partnerships in fostering innovation and operational efficiency across the biopharma industry.